Irritable bowel syndrome market forecast to more than triple to $1.52 billion in 2018

The market for irritable bowel syndrome drugs will more than triple from $459 million in 2008 to $1.52 billion in 2018 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from advisory firm Decision Resources.

The Pharmacor 2010 findings from the topic entitled Irritable Bowel Syndrome reveal that the primary driver of market growth will be the launches of several novel first-in-class therapies including Salix's Xifaxan (rifaximin), Ironwood/Forest/Almirall/Astellas' linaclotide, Tioga/Ono's asimadoline and Lexicon/Symphony Icon's LX-1031, beginning in the USA in 2011. Two of these therapies - linaclotide and asimadoline - have the potential to treat both motility and pain symptoms associated with irritable bowel syndrome, which will afford them a distinct advantage over currently available drugs, the report notes.

Linaclotide will push market growth